MABALL-RA (Rituximab) is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences. Rituximab is composed of two heavy chains of 451 amino acids and two light chains of 213 amino acids.
Rituximab is indicated for the treatment of: Non-Hodgkin's Lymphoma (NHL), Diagnosed Chronic Lymphocytic Leukaemia (CLL), Rheumatoid arthritis (RA), Add : Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA), I do not find this indication in PI: Phemphigus Vulgaris (PV)
* To be consumed as directed by physician.